Investigation of Cognitive Outcomes With Cannabidiol Oral Solution

Updated 05/17/2024

Status Withdrawn

Clinical Trial Summary

This study is being conducted to evaluate the effects of GWP42003-P on cognition in pediatric participants, aged 3 to 10 years, with Lennox-Gastaut Syndrome (LGS).

Clinical Trial Description

This trial is a 30-week (4-week baseline period; 26-week treatment period) open-label exploratory investigation of the effects of GWP42003-P on cognitive abilities in participants with LGS who reside in the United States. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04133480
Study type	Interventional
Source	Jazz Pharmaceuticals
Contact
Status	Withdrawn
Phase	Phase 4
Start date	October 2020
Completion date	December 2021

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT02632149` - Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome	Phase 0
	Recruiting	`NCT05626634` - Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy	Phase 2
	Completed	`NCT01151540` - A Long Term Extension Study of E2080 in Lennox-Gastaut Patients	Phase 3
	Completed	`NCT00552045` - Epilepsy Phenome/Genome Project
	Completed	`NCT00004776` - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome	Phase 3
	Withdrawn	`NCT03254680` - Turmeric as Treatment in Epilepsy	N/A
	Completed	`NCT01146951` - A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)	Phase 3
	Completed	`NCT01991041` - European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)	N/A
	Completed	`NCT01405053` - Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs	Phase 3
	Completed	`NCT02175173` - Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
	Completed	`NCT02224573` - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes	Phase 3
	Completed	`NCT00004729` - Ketogenic Diet for Child Epilepsy and Seizure Control	N/A
	Terminated	`NCT02815540` - The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy	Phase 1/Phase 2
	Withdrawn	`NCT02318537` - Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome	Phase 3
	Completed	`NCT01160770` - Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome	Phase 3
	Completed	`NCT03650452` - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies	Phase 2
	Withdrawn	`NCT01370486` - Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects	Phase 4
	Completed	`NCT02731300` - Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study	Phase 4
	Completed	`NCT02224690` - A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults	Phase 3